Eads & Heald Wealth Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.13M | Sell |
8,449
-819
| -9% | -$176K | 1.04% | 29 |
|
|
2026
Q1 | $2.02M | Sell |
9,268
-238
| -3% | -$52.8K | 1% | 40 |
|
|
2025
Q4 | $2.17M | Sell |
9,506
-453
| -5% | -$103K | 1.05% | 32 |
|
|
2025
Q3 | $2.31M | Sell |
9,959
-348
| -3% | -$70.9K | 1.1% | 27 |
|
|
2025
Q2 | $1.91M | Sell |
10,307
-64
| -0.6% | -$11.9K | 0.95% | 42 |
|
|
2025
Q1 | $2.17M | Sell |
10,371
-670
| -6% | -$130K | 1.1% | 32 |
|
|
2024
Q4 | $1.96M | Sell |
11,041
-62
| -0.6% | -$11.4K | 0.97% | 40 |
|
|
2024
Q3 | $2.19M | Sell |
11,103
-1,051
| -9% | -$196K | 1.04% | 39 |
|
|
2024
Q2 | $2.08M | Sell |
12,154
-396
| -3% | -$65.6K | 1.01% | 40 |
|
|
2024
Q1 | $2.29M | Sell |
12,550
-1,414
| -10% | -$244K | 1.07% | 32 |
|
|
2023
Q4 | $2.16M | Sell |
13,964
-16
| -0.1% | -$2.33K | 1.04% | 36 |
|
|
2023
Q3 | $2.08M | Sell |
13,980
-390
| -3% | -$57.3K | 1.09% | 35 |
|
|
2023
Q2 | $1.94M | Sell |
14,370
-503
| -3% | -$73.8K | 0.95% | 42 |
|
|
2023
Q1 | $2.37M | Sell |
14,873
-167
| -1% | -$25.5K | 1.17% | 28 |
|
|
2022
Q4 | $2.43M | Sell |
15,040
-21
| -0.1% | -$3.22K | 1.24% | 27 |
|
|
2022
Q3 | $2.02M | Buy |
15,061
+699
| +5% | +$100K | 1.15% | 34 |
|
|
2022
Q2 | $2.2M | Sell |
14,362
-258
| -2% | -$39.4K | 1.18% | 27 |
|
|
2022
Q1 | $2.37M | Sell |
14,620
-319
| -2% | -$46.3K | 1.1% | 34 |
|
|
2021
Q4 | $2.02M | Buy |
14,939
+256
| +2% | +$30.2K | 0.88% | 53 |
|
|
2021
Q3 | $1.58M | Buy |
14,683
+1,958
| +15% | +$224K | 0.77% | 62 |
|
|
2021
Q2 | $1.43M | Buy |
12,725
+6,976
| +121% | +$786K | 0.7% | 72 |
|
|
2021
Q1 | $622K | Buy |
5,749
+110
| +2% | +$11.8K | 0.32% | 100 |
|
|
2020
Q4 | $604K | Buy |
5,639
+87
| +2% | +$8.36K | 0.33% | 101 |
|
|
2020
Q3 | $486K | Buy |
5,552
+2,075
| +60% | +$195K | 0.29% | 102 |
|
|
2020
Q2 | $341K | Buy |
+3,477
| New | +$306K | 0.21% | 108 |
|
|
2020
Q1 | – | Sell |
-2,978
| Closed | -$264K | – | 119 |
|
|
2019
Q4 | $264K | Sell |
2,978
-35
| -1% | -$2.91K | 0.14% | 122 |
|
|
2019
Q3 | $228K | Sell |
3,013
-120
| -4% | -$8.23K | 0.13% | 125 |
|
|
2019
Q2 | $228K | Hold |
3,133
| – | – | 0.13% | 123 |
|
|
2019
Q1 | $252K | Buy |
3,133
+40
| +1% | +$3.27K | 0.15% | 119 |
|
|
2018
Q4 | $285K | Buy |
+3,093
| New | +$272K | 0.19% | 113 |
|
Other funds holding ABBV
Eads & Heald Wealth Management's ABBV Position: Q2 2026 in Review
Eads & Heald Wealth Management reduced its AbbVie (ABBV) stake by 8.8% in Q2 2026, selling an estimated $176K and leaving 8,449 shares worth $2.13M. The position accounts for 1.04% of the portfolio, ranked #29.
Eads & Heald Wealth Management first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $2.43M in Q4 2022. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Eads & Heald Wealth Management held 8,449 shares of AbbVie worth $2.13M as of Q2 2026.
- Eads & Heald Wealth Management sold 819 AbbVie shares in Q2 2026, an estimated $176K.
- AbbVie made up 1.04% of Eads & Heald Wealth Management's portfolio in Q2 2026, its #29 holding.
- Eads & Heald Wealth Management first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
- Eads & Heald Wealth Management's AbbVie position peaked at $2.43M in Q4 2022.
- 4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Eads & Heald Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.